SBIR Topic 097, Phase II - Early Detection and Monitoring of Cardiac Injury Due to Cardiotoxicity

SBIR 主题 097，第二阶段 - 心脏毒性引起的心脏损伤的早期检测和监测

• 批准号: 10056259
• 负责人: ALBERTO GANDINI
• 金额: $ 72.74万
• 依托单位: ACCEL DIAGNOSTICS, LLC
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-11-19 至 2020-11-18
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10056259
• 关键词: SBIR; Topic; 097; Phase; II

The goal of this contract is to encourage the development of innovative methods to detect and monitor cancer therapy-induced cardiac injury as early as possible through minimally invasive means. Early monitoring of cardiac injury will enhance both cardiac safety and treatment efficacy of cancer therapies. The contractor will develop a minimally invasive and rapid cardiovascular toxicity blood test device to monitor cancer patients undergoing chemotherapies. The device is a handheld, visual readout, semi-quantitative assay for measuring cardiac troponin I (TnI) and B-type natriuretic protein (BNP).

该合同的目标是鼓励开发创新方法，通过微创手段尽早检测和监测癌症治疗引起的心脏损伤。早期监测心脏损伤将提高心脏安全性和癌症治疗的疗效。承包商将开发一种微创快速心血管毒性血液检测装置，用于监测接受化疗的癌症患者。该设备是一种手持式、可视读出、半定量测定法，用于测量心肌肌钙蛋白 I (TnI) 和 B 型钠尿蛋白 (BNP)。